News for BioLife Solutions, Inc. (BLFS)

BioLife has improved its financials, with a dominant 70% market share in biopreservation media and high gross margins. Read why I'm neutral on BLFS stock.

Shares of BioLife Solutions Inc (BLFS) fell 0.28% in mid-day trading on Mar 22. The stock reached an intraday low of $24.19, before recovering slightly to $24

BioLife Solutions Inc (BLFS), a prominent developer and supplier of bioproduction tools and services for the cell and gene therapy market, announced on March 18

Shares of BioLife Solutions Inc (BLFS) fell 1.65% in mid-day trading on Mar 21. The stock reached an intraday low of $24.42, before recovering slightly to $25

PR NewswireBOTHELL, Wash., March 18, 2025 BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"

On February 28, 2025, Casdin Capital, LLC (Trades, Portfolio) executed a significant stock transaction involving Standard BioTools Inc. The firm added 9,609,638

Total Revenue 2024: $82 million, down from $143 million in 2023 due to divestitures.GAAP Gross Margin 2024: 62%, up from 31% in 2023.Adjusted EBITDA 2024: Posi

Comprehensive SWOT analysis based on BioLife Solutions Inc's latest SEC 10-K filing.Insightful exploration of the company's competitive edge, market challenges

Mar 03, 2025 / 01:00PM GMTOperator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q4 2024 shareholder and a

Shares of BioLife Solutions Inc (BLFS) surged 9.42% in mid-day trading on Mar 3. The stock reached an intraday high of $26.69, before settling at $26.32, up

Discover BioLife Solutions' (BLFS) Q4 earnings insights: EPS at -$0.06 (+80% Y/Y) & revenue at $21.73M (-33.6% Y/Y).

Shares of BioLife Solutions Inc (BLFS) surged 4.47% in mid-day trading on Feb 28. The stock reached an intraday high of $24.99, before settling at $24.64, u

BioLife Solutions Inc (BLFS) is set to release its Q4 2024 earnings on Mar 3, 2025. The consensus estimate for Q4 2024 revenue is $21.55 million, and the earnin

BioLife Solutions Inc (BLFS), a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has announced that

On December 31, 2024, Casdin Capital, LLC (Trades, Portfolio), a prominent investment firm, expanded its holdings in Neurogene Inc by acquiring an additional 27

BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.

If you are looking for stocks that are well positioned to maintain their recent uptrend, BioLife Solutions (BLFS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.